Women’s Health Today—April 29, 2026

This biweekly Women’s Health video recap highlights regulatory actions, access issues, clinical progress, AI-enabled tools, fertility benefits, and deal activity.

Dive deeper

In Today’s Newsletter

💼 Sun Pharma to acquire Organon [1] [India, US • 26 Apr 2026]

https://www.organon.com/news/sun-pharma-signs-definitive-agreement-to-acquire-organon/
Context: Sun Pharmaceutical Industries and Organon signed a definitive agreement approved by both boards.
Key point: Sun Pharma will acquire Organon for US$14.00 per share in cash, with an enterprise value of US$11.75 billion.
Implication: Signals pipeline investment and modality expansion.

🇨🇦 Duchesnay and PeriPharm flag Canada access gaps [2] [Canada • 22 Apr 2026]

https://www.newswire.ca/news-releases/duchesnay-and-peripharm-emphasize-the-need-to-update-regulatory-and-reimbursement-policies-to-improve-access-to-innovations-in-women-s-health-858284296.html
Context: The JOGC article analyzed women’s health products in Canada over 2003–2023.
Key point: Duchesnay and PeriPharm reported that Canadian women face delayed access to women’s health innovations and uneven public reimbursement.
Implication: May expand screening, initiation, and follow-up at scale.

🧬 Progyny launches insured fertility plan [3] [US • 16 Apr 2026]

https://www.globenewswire.com/news-release/2026/4/16/3275457/0/en/progyny-expands-access-to-fertility-and-women-s-health-with-industry-s-first-fully-insured-supplemental-plan.html
Context: Progyny Select is positioned for small US employers through a fixed premium, pooled-risk model.
Key point: Progyny launched a fully insured supplemental fertility and family-building plan covering IVF, IUI, genetic testing, navigation, and women’s health support.
Implication: May expand screening, initiation, and follow-up at scale.

🤖 NCCN highlights AI mammogram-based risk assessment [4] [US • 14 Apr 2026]

https://www.bcrf.org/blog/a-revolution-in-breast-cancer-prevention-is-underway-with-ai-mammogram-based-risk-assessment-starting-at-35/
Context: BCRF describes 2026 NCCN Breast Cancer Screening and Diagnosis guidance on AI-based 5-year risk assessment from mammograms.
Key point: NCCN guidance includes AI mammogram-based risk assessment beginning at age 35, using a 5-year risk threshold to guide clinical action.
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 Artera gains EU CE marks for AI oncology assays [5] [EU • 21 Apr 2026]

https://www.businesswire.com/news/home/20260421256856/en/Artera-Secures-CE-Marking-for-Its-AI-Prostate-and-Breast-Cancer-Assays-Unlocking-Global-Expansion
Context: Artera secured CE marking under EU IVDR for ArteraAI Prostate Biopsy Assay and ArteraAI Breast Cancer Assay.
Key point: The CE marks enable clinical use across EU member states and EFTA countries named by the source.
Implication: May expand screening, initiation, and follow-up at scale.

💊 Afuresertib combination meets Phase 3 primary endpoint [6] [16 Apr 2026]

https://www.targetedonc.com/view/afuresertib-based-combination-meets-primary-end-point-in-phase-3-hr-breast-cancer-trial
Context: AFFIRM-205 enrolled patients with HR+/HER2– locally advanced or metastatic breast cancer with PIK3CA/AKT1/PTEN alterations.
Key point: Afuresertib plus fulvestrant met the primary PFS endpoint versus placebo plus fulvestrant.
Implication: May influence prescriber choice and payer reviews pending full data.

🎯 Mabwell starts Phase 3 Nectin-4 ADC trial in TNBC [7] [China • 23 Apr 2026]

https://www.prnewswire.com/news-releases/mabwell-initiates-phase-iii-clinical-study-of-its-nectin-4-targeting-adc-9mw2821-for-the-treatment-of-triple-negative-breast-cancer-302751535.html
Context: Mabwell initiated a randomized, open-label, controlled, multicenter Phase 3 study of 9MW2821 in locally advanced or metastatic TNBC.
Key point: 9MW2821 is being compared with investigator’s choice of chemotherapy after prior taxane-based chemotherapy and TOPi-ADC exposure.
Implication: May influence prescriber choice and payer reviews pending full data.

🧫 Mabwell 9MW2821 cervical cancer case report appears in NEJM [8] [China • 22 Apr 2026]

https://www.manilatimes.net/2026/04/22/tmt-newswire/pr-newswire/case-report-of-mabwells-nectin-4-targeting-adc-9mw2821-in-cervical-cancer-published-in-the-new-england-journal-of-medicine/2325590
Context: A case report described hepatic pseudoprogression after 9MW2821 in metastatic cervical squamous-cell carcinoma.
Key point: Mabwell said the patient continued treatment after biopsy ruled out viable tumor cells, with later resolution of the liver lesion.
Implication: May influence prescriber choice and payer reviews pending full data.

Why It Matters

Women’s health access remains a policy and reimbursement issue, with Canada-focused evidence highlighting delayed access to innovations.
AI-enabled risk assessment and pathology tools are moving from research settings into guideline and regulatory pathways.
Fertility and family-building benefits are expanding beyond large-employer markets through insured supplemental models.
AKT and Nectin-4 programs continue to advance in breast and gynecologic cancers with late-stage and case-based evidence.
BD activity remains active in women’s health, established brands, and biosimilars.

📚 View the full Women’s health archive on our research hub page.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

🎯 Catch up on the Top Women’s Health news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What is Sun Pharma buying from Organon?

Sun Pharma agreed to acquire all outstanding Organon shares for cash. Organon brings women’s health, general medicines, biosimilars, and a global commercial footprint. [1]

What did Duchesnay and PeriPharm report about Canadian women’s health access?

They reported gaps and delays in access to women’s health medicines in Canada, including slower public coverage versus other medicines. [2]

What is Progyny Select?

Progyny Select is a fully insured supplemental fertility and family-building plan for small US employers, using fixed PEPM pricing. [3]

What role does Clairity Breast play in AI mammogram-based risk assessment?

The BCRF article identifies Clairity Breast as an FDA-approved AI platform using a single mammogram to estimate 5-year breast cancer risk. [4]

What did Artera receive CE marking for?

Artera received CE marking under EU IVDR for ArteraAI Prostate Biopsy Assay and ArteraAI Breast Cancer Assay. [5]

What is Mabwell’s 9MW2821?

9MW2821, also called bulumtatug fuvedotin in the cervical cancer item, is Mabwell’s Nectin-4-targeting ADC being studied in TNBC and cervical cancer. [7,8]

Entities / Keywords

Sun Pharmaceutical Industries, Sun Pharma, Organon, Organon & Co., women’s health, biosimilars, established brands
Duchesnay, Duchesnay Pharmaceutical Group, PeriPharm, JOGC, Canada reimbursement, women’s health access
Progyny, Progyny Select, fertility benefits, family building, IVF, IUI, small employers
NCCN, BCRF, Clairity Breast, AI mammogram, 5-year breast cancer risk, precision prevention
Artera, ArteraAI Prostate Biopsy Assay, ArteraAI Breast Cancer Assay, EU IVDR, CE marking, multimodal AI
Afuresertib, LAE002, fulvestrant, AFFIRM-205, HR+/HER2– breast cancer, PIK3CA, AKT1, PTEN
Mabwell, 9MW2821, bulumtatug fuvedotin, Nectin-4 ADC, TNBC, cervical cancer, NEJM